Caption Management’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-536,838
| Closed | -$11.6M | – | 1552 |
|
|
2025
Q4 | $11.6M | Buy |
536,838
+228,393
| +74% | +$4.43M | 0.08% | 300 |
|
|
2025
Q3 | $4.71M | Buy |
308,445
+43,535
| +16% | +$566K | 0.04% | 516 |
|
|
2025
Q2 | $2.34M | Hold |
264,910
| – | – | 0.03% | 673 |
|
|
2025
Q1 | $2.07M | Buy |
+264,910
| New | +$2.22M | 0.02% | 668 |
|
|
2024
Q4 | – | Sell |
-123,002
| Closed | -$1.49M | – | 1449 |
|
|
2024
Q3 | $1.61M | Buy |
123,002
+118,502
| +2,633% | +$1.81M | 0.03% | 635 |
|
|
2024
Q2 | $63.3K | Sell |
4,500
-31,596
| -88% | -$515K | ﹤0.01% | 1046 |
|
|
2024
Q1 | $610K | Sell |
36,096
-29,012
| -45% | -$432K | 0.01% | 837 |
|
|
2023
Q4 | $919K | Sell |
65,108
-15,992
| -20% | -$188K | 0.01% | 826 |
|
|
2023
Q3 | $835K | Buy |
81,100
+13,907
| +21% | +$186K | 0.01% | 808 |
|
|
2023
Q2 | $1.11M | Sell |
67,193
-48,311
| -42% | -$628K | 0.02% | 635 |
|
|
2023
Q1 | $1.06M | Buy |
+115,504
| New | +$950K | 0.02% | 621 |
|
|
2022
Q1 | – | Sell |
-190,000
| Closed | -$1.54M | – | 1452 |
|
|
2021
Q4 | $1.54M | Buy |
190,000
+40,000
| +27% | +$366K | 0.02% | 880 |
|
|
2021
Q3 | $1.47M | Buy |
150,000
+105,808
| +239% | +$833K | 0.02% | 892 |
|
|
2021
Q2 | $298K | Hold |
44,192
| – | – | ﹤0.01% | 1132 |
|
|
2021
Q1 | $400K | Buy |
+44,192
| New | +$357K | 0.01% | 851 |
|
|
2020
Q4 | – | Sell |
-84,600
| Closed | -$427K | – | 964 |
|
|
2020
Q3 | $427K | Buy |
+84,600
| New | +$616K | 0.01% | 805 |
|
Other funds holding AVDL
Caption Management's AVDL Position: Q1 2026 in Review
Caption Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 536,838 shares — an estimated $11.6M sold.
Caption Management first reported a position in AVDL in Q3 2020 and held it in 16 quarters. The position peaked at $11.6M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Caption Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Caption Management sold 536,838 Avadel Pharmaceuticals shares in Q1 2026, an estimated $11.6M.
- Caption Management first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 16 quarters.
- Caption Management's Avadel Pharmaceuticals position peaked at $11.6M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.